Kirkland Represents Montes Archimedes Acquisition Corp. in Business Combination with Roivant Sciences

Kirkland & Ellis advised Montes Archimedes Acquisition Corp. (NASDAQ: MAAC), a special purpose acquisition company sponsored by Patient Square Capital, on its business combination agreement with Roivant Sciences, a biopharmaceutical and healthcare technology company. Upon closing of the transaction, Roivant Sciences is expected to be listed on NASDAQ under the new ticker symbol “ROIV,” and the company is expected to have an have an initial market capitalization of $7.3 billion inclusive of its pro forma net cash balance of approximately $2.3 billion. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2021. 
 
Read the Montes Archimedes press release 
 
The Kirkland team was led by corporate partners Ryan Brissette and Michael Weisser and associates Christopher Burwell, James Long, Arjun Karthikeyan and Justin Prindle, capital markets partners Sophia Hudson and Sharon Freiman and associates Anthony Zangrillo and Kyle Unice, restructuring associates Patrick Venter, Jordan Elkin and Maddison Levine, and tax partners Jared Rusman and William Dong and associate Nicole Martin.